Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
2001 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
2002 Apheresis Allogeneic Primary myelofibrosis Hematology 2024 Standard Therapy Germany 55
2003 Apheresis Autologous Amyloid Light-Chain Amyloidosis Hematology 2024 Standard Therapy Germany 55
2004 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 61
2005 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
2006 Apheresis Autologous Epstein–Barr Virus Positive Diffuse Large B-Cell Lymphoma Hematology 2024 Standard Therapy Germany 63
2007 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 69
2008 Apheresis Autologous Angioimmunoblastic T-cell lymphoma Hematology 2024 Standard Therapy Germany 58
2009 Apheresis Allogeneic Acute lymphoblastic leukemia Hematology 2024 Standard Therapy Germany 19
2010 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 66
2011 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 61
2012 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Canada 16
2013 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 61
2014 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 75
2015 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2024 Standard Therapy USA 62
2016 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2024 Standard Therapy France 66
2017 Apheresis Allogeneic B-Cell Lymphoma Hematology 2024 Standard Therapy Canada 70
2018 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 60
2019 Apheresis Allogeneic Myeloma Multiplex Hematology 2024 Standard Therapy Poland 57
2020 Apheresis Allogeneic Diffuse large B-cell lymphoma Hematology 2024 Standard Therapy Poland 17
2021 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 48
2022 Apheresis Allogeneic Chronic lymphocytic leukemia Hematology 2024 Standard Therapy Germany 63
2023 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 65
2024 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 64
2025 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 76
2026 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 44
2027 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 62
2028 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy NETHERLANDS 25
2029 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy USA 42
2030 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy CROATIA 66
2031 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 70
2032 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Switzerland 68
2033 Apheresis Allogeneic Chronic Myelomonocytic Leukaemia Hematology 2024 Standard Therapy NETHERLANDS 62
2034 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2024 Standard Therapy USA 58
2035 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 62
2036 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Belarus 54
2037 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Spain 9
2038 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 66
2039 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 67
2040 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 54
2041 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy South Africa 54
2042 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 60
2043 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Sweden 60
2044 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Spain 67
2045 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 66
2046 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 53
2047 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 65
2048 Apheresis Autologous Non-Hodgkin Lymphoma, rezidiv Hematology 2024 Standard Therapy Germany 64
2049 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 57
2050 Apheresis Allogeneic Acute myeloid leukemia Hematology 2024 Standard Therapy Germany 66
2051 Apheresis Allogeneic Acute lymphoblastic leukemia Hematology 2024 Standard Therapy Germany 50
2052 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 57
2053 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 70
2054 Apheresis Allogeneic Multiple Organ Dysfunction Syndrome Hematology 2024 Standard Therapy Germany 42
2055 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 32
2056 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 76
2057 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Italy 63
2058 Apheresis Allogeneic Early T-cell precursor Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Australia 43
2059 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 72
2060 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 72
2061 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 52
2062 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 73
2063 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy Poland 68
2064 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Italy 63
2065 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Czechia 46
2066 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy France 64
2067 Apheresis Allogeneic Primary Immunodeficiencies Hematology 2024 Standard Therapy Russia 7
2068 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 68
2069 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 62
2070 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 48
2071 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy USA 63
2072 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Spain 58
2073 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 41
2074 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2024 Standard Therapy USA 73
2075 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 15
2076 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Germany 65
2077 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 38
2078 Apheresis Allogeneic Plasmacytoma Hematology 2024 Standard Therapy Poland 46
2079 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Portugal 60
2080 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Portugal 60
2081 Skeletal Muscle Allogeneic – Related Duchenne Muscular Dystrophy (DMD) Genetic disorder 2023 Experimental Therapy Poland 8
2082 Skeletal Muscle Allogeneic – Related Duchenne Muscular Dystrophy (DMD) Genetic disorder 2023 Experimental Therapy Poland 16
2083 Cord Tissue Allogeneic – Related Ags (Autism + Epilepsy) Neurology 2023 Experimental Therapy Poland/Romania 15
2084 Cord Tissue Allogeneic – Related Autism Neurology 2023 Experimental Therapy Romania 8,5
2085 Cord Tissue Autologous Autism Neurology 2023 Experimental Therapy Hungary 10
2086 Cord Tissue Allogeneic – Related Autism Neurology 2023 Experimental Therapy Romania 4
2087 Cord Tissue Allogeneic – Related Autism Neurology 2023 Experimental Therapy Romania 10
2088 Cord Tissue Allogeneic – Related Autism Neurology 2023 Experimental Therapy Romania 3,2
2089 Cord Tissue Autologous Cerebral Palsy Neurology 2023 Experimental Therapy Romania 2
2090 Cord Tissue Allogeneic – Related Cerebral Palsy Neurology 2023 Experimental Therapy Romania 3
2091 Cord Tissue Allogeneic – Unrelated Disorders Of Optic Nerve Ophthalmology 2023 Experimental Therapy Poland 39,1
2092 Cord Tissue Allogeneic – Unrelated Gonarthrosis Orthopedy 2023 Experimental Therapy Poland 65,1
2093 Cord Tissue Allogeneic – Unrelated Gonarthrosis Orthopedy 2023 Experimental Therapy Poland 50,8
2094 Cord Tissue Allogeneic – Unrelated Graft Versus Host Disease Hematology 2023 Experimental Therapy Poland 8 months
2095 Cord Tissue Allogeneic – Unrelated Graft Versus Host Disease Hematology 2023 Experimental Therapy Poland 16,2
2096 Cord Tissue Allogeneic – Unrelated Internal Damage To The Knee Joint Orthopedy 2023 Experimental Therapy Poland 20,8
2097 Cord Tissue Allogeneic – Unrelated Internal Damage To The Knee Joint Orthopedy 2023 Experimental Therapy Poland 49,8
2098 Cord Tissue Allogeneic – Unrelated Internal Damage To The Knee Joint Orthopedy 2023 Experimental Therapy Poland 62,7
2099 Cord Tissue Allogeneic – Unrelated Internal Damage To The Knee Joint Orthopedy 2023 Experimental Therapy Poland 24,1
2100 Cord Tissue Allogeneic – Unrelated Mucopolysaccharidosis Type Ii Hematology 2023 Experimental Therapy Poland 4,7